- Home
- IMNM vs DIN Comparison
IMNM vs DIN Comparison
Compare IMNM & DIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- DIN
- Stock Information
- Founded
- IMNM 2006
- DIN 1958
- Country
- IMNM United States
- DIN United States
- Employees
- IMNM N/A
- DIN N/A
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- DIN Restaurants
- Sector
- IMNM Health Care
- DIN Consumer Discretionary
- Exchange
- IMNM Nasdaq
- DIN Nasdaq
- Market Cap
- IMNM 585.5M
- DIN 494.3M
- IPO Year
- IMNM 2020
- DIN 1991
- Fundamental
- Price
- IMNM $9.99
- DIN $26.64
- Analyst Decision
- IMNM Strong Buy
- DIN Hold
- Analyst Count
- IMNM 5
- DIN 8
- Target Price
- IMNM $28.60
- DIN $37.00
- AVG Volume (30 Days)
- IMNM 881.8K
- DIN 612.7K
- Earning Date
- IMNM 11-13-2024
- DIN 02-26-2025
- Dividend Yield
- IMNM N/A
- DIN 7.66%
- EPS Growth
- IMNM N/A
- DIN 25.34
- EPS
- IMNM N/A
- DIN 6.02
- Revenue
- IMNM $10,129,000.00
- DIN $813,838,000.00
- Revenue This Year
- IMNM N/A
- DIN N/A
- Revenue Next Year
- IMNM N/A
- DIN $0.63
- P/E Ratio
- IMNM N/A
- DIN $4.42
- Revenue Growth
- IMNM N/A
- DIN N/A
- 52 Week Low
- IMNM $8.97
- DIN $25.68
- 52 Week High
- IMNM $30.96
- DIN $51.35
- Technical
- Relative Strength Index (RSI)
- IMNM 40.28
- DIN 32.02
- Support Level
- IMNM $9.24
- DIN $26.30
- Resistance Level
- IMNM $11.06
- DIN $27.90
- Average True Range (ATR)
- IMNM 0.74
- DIN 1.08
- MACD
- IMNM -0.06
- DIN -0.19
- Stochastic Oscillator
- IMNM 31.78
- DIN 16.38
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
About DIN Dine Brands Global Inc.
Dine Brands Global Inc owns and franchises thousands of restaurants under the Applebee's and International House of Pancakes names. Almost all company restaurants are located in the United States and franchised. Royalty revenue, which the company gets from franchisees based on franchisees' sales, accounts for roughly three-quarters of total company revenue. The company also earns revenue by leasing restaurant sites to franchisees. The company has four reportable segments Franchise operations, (an aggregation of Applebee's and IHOP franchise operations), Rental operations, Financing operations, and Company-operated restaurant operations. The majority of revenue is derived from the Franchise operations segment.